Comparative Pharmacology
Head-to-head clinical analysis: LIKMEZ versus ZAVESCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIKMEZ versus ZAVESCA.
LIKMEZ vs ZAVESCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIKMEZ is a combination of atorvastatin and ezetimibe. Atorvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL receptor expression. Ezetimibe inhibits intestinal cholesterol absorption by blocking the NPC1L1 transporter.
Inhibits glucosylceramide synthase, reducing synthesis of glycosphingolipids including glucocerebroside.
100 mg orally twice daily
100 mg orally three times daily.
None Documented
None Documented
Terminal half-life: 12 hours (range 10-14 h); clinical context: allows once-daily dosing for most patients.
6-7 hours; in patients with hepatic impairment, up to 12-15 hours.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Renal (predominantly): 70% unchanged, fecal: 20% as metabolites, biliary: minor.
Category C
Category C
Glucosylceramide Synthase Inhibitor
Glucosylceramide Synthase Inhibitor